Jon E. Angell

Array ( [id] => 17593406 [patent_doc_number] => 20220142979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/277562 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895369 [patent_doc_number] => 20220305031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHODS FOR REDUCING TUMOR PROGRESSION AND FIBROSIS AND INCREASING ADAPTIVE IMMUNITY IN MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/618302 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548725 [patent_doc_number] => 12559504 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Benzotriazole derivative [patent_app_type] => utility [patent_app_number] => 17/614941 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93313 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 623 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990657 [patent_doc_number] => 20210229077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => OXIDE CATALYST AND METHOD FOR PRODUCING UNSATURATED NITRILE [patent_app_type] => utility [patent_app_number] => 17/281481 [patent_app_country] => US [patent_app_date] => 2020-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718999 [patent_doc_number] => 20220211718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => BCL-2 INHIBITORS FOR USE IN THE TREATMENT OF A BCL-2 MEDIATED CANCER CARRYING THE GLY101VAL MUTATION [patent_app_type] => utility [patent_app_number] => 17/609874 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790377 [patent_doc_number] => 20220249468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY [patent_app_type] => utility [patent_app_number] => 17/602915 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855522 [patent_doc_number] => 12258344 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Azaaromatic amide derivatives for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/599806 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28716 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20106914 [patent_doc_number] => 12357612 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Prophylactic or therapeutic agent for cancer [patent_app_type] => utility [patent_app_number] => 17/442173 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 1038 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17656997 [patent_doc_number] => 20220177462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/442064 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627177 [patent_doc_number] => 20220162192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => INDAZOLES AS LRRK2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/440872 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 732 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609752 [patent_doc_number] => 20220152031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => PYRIDAZINONES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/440928 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20341886 [patent_doc_number] => 12465601 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Uses of phosphodiesterase inhibitors [patent_app_type] => utility [patent_app_number] => 17/436879 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 18396 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641934 [patent_doc_number] => 20220169672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/434672 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020543 [patent_doc_number] => 20220372042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/764285 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 1132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749529 [patent_doc_number] => 20220227733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => PD-L1 ANTAGONIST COMPOUND [patent_app_type] => utility [patent_app_number] => 17/281251 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702942 [patent_doc_number] => 20220202948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Agent for Eliminating Pluripotent Stem Cells [patent_app_type] => utility [patent_app_number] => 17/430312 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532278 [patent_doc_number] => 20220110887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/429259 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036169 [patent_doc_number] => 20220380384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => INTERNAL CYCLIC SULPHIAMIDINE AMIDE-ARYL AMIDE COMPOUND AND USE THEREOF FOR TREATING HEPATITIS B [patent_app_type] => utility [patent_app_number] => 17/421819 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 628 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16488022 [patent_doc_number] => 20200381631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOUND, DISPLAY PANEL AND DISPLAY APPARATUS [patent_app_type] => utility [patent_app_number] => 16/732110 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 220 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904097 [patent_doc_number] => 12281093 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => 3-(1,2,3,6-tetrahydropyridin-2-YL) pyridine glutarate or a pharmaceutically acceptable solvate thereof [patent_app_type] => utility [patent_app_number] => 17/289794 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 11548 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289794 [rel_patent_id] =>[rel_patent_doc_number] =>)